Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zavzpret (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Zavegepant is effective in providing pain relief within 2 hours and sustained pain relief over 24 hours but is less effective compared to lasmiditan (100 mg, 200 mg), rimegepant (75 mg), and zolmitriptan (5 mg).
• Zavegepant shows a trend towards reduced pain relapse between 2 to 48 hours, but the difference was not statistically significant. It is also less effective in achieving freedom from nausea, phonophobia, and photophobia compared to DFN-02 and ROX-828.
• Zavegepant demonstrates significant improvement in freedom from most bothersome symptoms (MBS) at 2 hours. However, in comparative effectiveness, zolmitriptan (5 mg) and rimegepant (75 mg) are more effective in other measured outcomes.
• Zavegepant demonstrated the lowest risk of adverse events (AEs) among intranasal agents studied (OR: 2.04, 95% CI: 1.37 to 3.03), while dihydroergotamine nasal spray had the highest risk (OR: 9.65, 95% CI: 4.39 to 21.22).
• Lasmiditan was associated with a high incidence of adverse effects, including dizziness, somnolence, asthenia, paresthesia, and fatigue.
• There is no population types or subgroups information available in the reviewed studies.